Some of the best biotech opportunities can be found in oversold obesity treatment stocks. Look at Eli Lilly, for example.
|
Company: Eli Lilly (SYM: LLY) The last time I mentioned LLY, I said, “Oversold shares of Eli Lilly could easily bounce higher on sales of its obesity drugs. And it could easily jump higher with its Zepbound drug being considered for the treatment of sleep apnea.” That was on July 30, as the stock traded at about $780. Today, it’s already up to $893.04 and could easily push aggressively higher thanks to growing demand for its obesity treatments and strong earnings. And, again thanks to obesity treatments, it raised guidance well above estimates. |
Millionaire Publishing
Got 14 minutes?
Then you have time to learn the unusual market loophole Tim Sykes uses to earn $8,780, $9,518 and even $16,159 on the weekend.
(While the market is closed)
>>>Watch the amazing 14 min video now.
|
However, LLY isn’t the only obesity treatment stock worth paying attention to. There’s also: Company: Viking Therapeutics (SYM: VKTX) Now trading at $57, VKTX could run back to all-time highs, as it nears Phase 3 trials for its obesity treatment, VK2735. The company just announced plans to start a late-stage trial for its obesity drug VK2735 later this year. “We are advancing this compound into Phase 3 development,” CEO Brian Lian said, as noted in a company press release, adding that “we are currently preparing for an end-of-phase 2 meeting with the agency, which we expect to occur later this year.” In addition, Phase 1 trials of the oral form of the treatment showed encouraging safety and tolerability, with positive signs of clinical activity, as noted in a company press release. Patients also reported a mean weight loss of up to 5.3% from baseline after 28 days. The company expects to move into Phase 2 with the oral treatment later this year. |
Simpler Trading
FREE training: The day trading strategy behind Tr3ndy Jon’s +80% win rate
What if you could anticipate major market turns … even in highly volatile conditions that appear “random”? The “Big Players” are behind the big moves, but most traders don’t know how to read their order flow. We’ll show you how to do this with my “supply and demand” day trading system. Using this strategy, we’re seeing an +80% win rate. Want to learn more?
Check out my FREE training here.
|
Company: Structure Therapeutics (SYM: GPCR) The company recently reported positive topline data from its Phase 2a obesity study of GSBR-1290, which “demonstrated a clinically meaningful and statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks,” according to a company press release. GPCR is also on track to initiate a 36-week Phase 2b study of GSBR-1290 in the fourth quarter of the year. Should it continue to show solid progress, shares of GPCR could easily push aggressively higher. Even better, JPMorgan analysts noted: “We think the opportunity for oral GLP-1s is underappreciated and think this market could generate $30bn in sales by 2035. GPCRs lead asset, 1290, is a pure-play option for this opportunity, and even a small share would support substantial upside to the stock.” |
